FibroGen, Inc. (FGEN)

FibroGen, Inc. is a biopharmaceutical company founded in 1993 and headquartered in San Francisco, California. The company is focused on developing innovative therapies to treat serious unmet medical needs, particularly in the areas of fibrosis, anemia, and cancer. FibroGen's notable work includes the development of roxadustat, a treatment for anemia associated with chronic kidney disease. The company is dedicated to advancing science in the field of fibrosis and behind its pioneering research is committed to improving patient outcomes. As of the latest data, Enrique Conterno serves as CEO, bringing extensive experience in the pharmaceutical industry to lead the company towards future growth and innovation. FibroGen remains a key player in biotechnology, with a robust pipeline and ongoing research efforts.